Zynerba Pharmaceuticals Inc is about to embark upon a journey with unknown destinations, as investors brace for a trio of reads from the company in the third quarter of 2017.Focus: 3 Phase 2 Reads Of ZYN002Cantor Fitzgerald said in a note released Monday it remains focused on three key mid-stage trial results of Zynerba Pharma's ZYN002, testing it for adult epilepsy, pain due to osteoarthritis, or OA, and fragile X syndrome, or FXS.ZYN002 is a synthetic cannabidiol, or CBD, formulated as a permeation-enhanced gel for transdermal delivery. CBD is one of the many active cannabinoids identified in cannabis.Following the company's fourth-quarter earnings call, analyst Elemer Piros said he is encouraged by the results of separate clinical studies using CBD in the treatment of epilepsy. This, according to the analyst, supports the potential for a positive readout with ZYN002.Source